Avalo Therapeutics, Inc. · NASDAQ:AVTX

Doyle Mittie sold 108,234 Avalo Therapeutics, Inc. shares (Form 4)

Traded May 5 to May 6, 2026 · Filed May 7, 2026

From May 5 to May 6, 2026, Doyle Mittie (Chief Medical Officer) sold 108,234 Avalo Therapeutics, Inc. shares at an average US$20.61 for US$2.23M under a trading plan, leaving 3,622 shares. Filed May 7, 2026 (Form 4).

Sold
108,234 shares
Price
US$20.61 average (US$16.00 to US$22.88)
Value
US$2.23M
Holding after
3,622 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Medical Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 5, 2026Common StockOption exercise1,000US$12.654,622Direct
May 5, 2026Common StockOption exercise679US$8.045,301Direct
May 5, 2026Common StockSale1,679US$16.003,622Direct
May 6, 2026Common StockOption exercise77,905US$12.6581,527Direct
May 6, 2026Common StockOption exercise28,650US$8.04110,177Direct
May 6, 2026Common StockSale27,538US$18.0382,639Direct
May 6, 2026Common StockSale5,000US$19.6577,639Direct
May 6, 2026Common StockSale44,944US$21.2032,695Direct
May 6, 2026Common StockSale19,015US$22.4113,680Direct
May 6, 2026Common StockSale10,058US$22.883,622Direct

Source

View original at SEC

Related